ストックスクリーナーアプリを入手
0.4502
3.60%
-0.0168
アフターアワーズ：
.45
-0.0002
-0.04%
前日終値:
$0.467
開ける：
$0.459
24時間の取引高:
612.64K
Relative Volume:
0.65
時価総額：
$129.27M
収益：
$54,000
当期純損益:
$-210.26M
株価収益率:
-0.5699
EPS:
-0.79
ネットキャッシュフロー:
$-159.01M
1週間 パフォーマンス:
+3.83%
1か月 パフォーマンス:
-14.28%
6か月 パフォーマンス:
-51.43%
1年 パフォーマンス:
-79.54%
1日の値動き範囲:
$0.4217
$0.478
1週間の範囲:
$0.4217
$0.49
52週間の値動き範囲:
$0.3931
$2.875
Lyell Immunopharma Inc Stock (LYEL) Company Profile
名前
Lyell Immunopharma Inc
セクター
電話
650 695-0677
住所
201 HASKINS WAY, SOUTH SAN FRANCISCO
LYEL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
0.4502 | 129.27M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-30 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-06-27 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-11-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | BofA Securities | Buy |
| 2021-07-12 | 開始されました | Goldman | Buy |
| 2021-07-12 | 開始されました | JP Morgan | Overweight |
| 2021-07-12 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Lyell Immunopharma Inc (LYEL) 最新ニュース
A better buy-in window may exist right now for Lyell Immunopharma Inc (LYEL) - Sete News
Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 35,640 shares worth 19958.0. - knoxdaily.com
Can you now get a good deal on Lyell Immunopharma Inc’s shares? - uspostnews.com
Lyell Immunopharma’s (LYEL) Neutral Rating Reiterated at HC Wainwright - Defense World
FDA grants RMAT status to Lyell’s lymphoma therapy By Investing.com - Investing.com South Africa
Lyell Immunopharma gets FDA RMAT status for lymphoma treatment - Seeking Alpha
FDA grants RMAT status to Lyell’s lymphoma therapy - Investing.com
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma - GlobeNewswire
Breakthrough Cancer Treatment Gets FDA Special Status: 94% Success in Lymphoma Patients - Stock Titan
Prudential Financial Inc. Cuts Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa
Lyell Immunopharma stock hits 52-week low at $0.4 - Investing.com
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition - Fierce Pharma
Lyell Immunopharma stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
Lyell Immunopharma director Otis Brawley purchases shares for $19,958 By Investing.com - Investing.com India
Lyell Immunopharma director Otis Brawley purchases shares for $19,958 - Investing.com
Lyell Immunopharma stock hits 52-week low at $0.48 - Investing.com
Lyell Immunopharma to close West Hills facility, cut 73 jobs By Investing.com - Investing.com India
Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production - TipRanks
Lyell Immunopharma to close West Hills facility, cut 73 jobs - Investing.com
Lyell Immunopharma IncTo Close West Hills Manufacturing FacilitySEC Filing - MarketScreener
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Decline in Short Interest - MarketBeat
Charles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 200,000 shares worth 0.12 million. - knoxdaily.com
Wednesday 3/26 Insider Buying Report: LYEL, LSAK - Nasdaq
Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock - Investing.com
Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock By Investing.com - Investing.com South Africa
15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey
Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report - markets.businessinsider.com
Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock - Yahoo Finance
Chief Financial Officer of Lyell Immunopharma Charles Newton Buys 989% More Shares - simplywall.st
How to interpret Lyell Immunopharma Inc (LYEL)’s stock chart patterns - US Post News
Lyell Immunopharma stock hits 52-week low at $0.51 By Investing.com - Investing.com Australia
Lyell Immunopharma director Richard Klausner purchases $94,942 in stock - Investing.com India
Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock By Investing.com - Investing.com South Africa
Lyell Immunopharma director Richard Klausner purchases $94,942 in stock By Investing.com - Investing.com Canada
Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com - Investing.com South Africa
Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock - Investing.com India
Lyell Immunopharma CFO Newton purchases $111,620 in common stock - Investing.com India
Lyell Immunopharma stock hits 52-week low at $0.51 - Investing.com India
Lyell Immunopharma’s Global Expansion Strategy: Navigating Risks and Challenges - TipRanks
HC Wainwright Has Optimistic Outlook of LYEL Q1 Earnings - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright - Defense World
H.C. Wainwright maintains Neutral on Lyell Immunopharma stock By Investing.com - Investing.com Australia
Lyell Immunopharma Inc (LYEL) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):